Interim Report January – September 2017
BioArctic listed on Nasdaq Stockholm Mid Cap July - September 2017 · Net sales for the period amounted to SEK 31.5 million (1.2) · Operating profit amounted to SEK 0.6 million (-10.2) · Loss for the period amounted to SEK -0.1 million (-7.8) · Earnings per share SEK 0.00 (-0.12) · Cash flow from operating activities amounted to SEK -23.6 million (-9.8) January - September 2017 · Net sales for the period amounted to SEK 89.7 million (11.2) · Operating profit amounted to SEK 4.6 million (-22.7) · Profit/loss for the period amounted to SEK 3.3 million (